

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	3-4
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	5-6
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	6
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	N/A
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	7
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	6-7
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	6-7
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	8
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	8-9
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	8-9
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	8
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	8-9
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis.	8-9




Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	9
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	9
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	9,Figure 1
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	9-11,Table 1
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	12,Figure 2
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	12-15, Figure 3-7
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	15-16, Figure 3-7
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	16
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	16
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	16-17
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	19
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	19-20
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	20-21

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097

Supplementary Materials 1: Plots of subgroup analyses

	Sher	igmai injecti		Basic treatment				Mean Difference	Mean Difference	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl	
3.2.1 ≥ 60 ml										
Chen 2010	25	6.557439	50	11	5.567764	50	5.7%	14.00 [11.62, 16.38]		
Dou 2010	10.7	6.221736	30	5.6	6.062178	23	5.3%	5.10 [1.77, 8.43]		
_ai 2018	4.28	2.608237	65	2.21	2.590926	65	6.0%	2.07 [1.18, 2.96]	+	
Ni 2012	7.58	5.467111	43	5.92	5.498036	41	5.7%	1.66 [-0.69, 4.01]	and the second	
Pan 2013	12.44	4.809626	34	7.05	4.263942	34	5.7%	5.39 [3.23, 7.55]	the second se	
Sun 2013	19.1	4.70319	30	9.9	4.32088	30	5.7%	9.20 [6.91, 11.49]		
Nu 2013	11.29	6.40353	30	3.51	6.290564	22	5.2%	7.78 [4.29, 11.27]		
(u 2004	8.9	7.312318	50	4.6	7.053368	26	5.3%	4.30 [0.91, 7.69]		
Subtotal (95% CI)			332			291	44.6%	6.16 [3.03, 9.29]	•	
Heterogeneity: Tau ² = Fest for overall effect:				(P < 0.0)	0001); I¥ = 9	4%				
i.2.2 < 60 ml										
Chi 2017	19.4	4.687217	40	13.4	4.553021	40	5.8%	6.00 [3.97, 8.03]		
Ding 2012	7.54	3.834697	40	4.79	4.2265	40	5.8%	2.75 [0.98, 4.52]		
(ong 2004	20	4.582576	30	6	4.582576	30	5.7%	14.00 [11.68, 16.32]		
Vang 2010	22	7	41	12	6.082763	41	5.5%	10.00 [7.16, 12.84]		
Ven 2013	27	5.567764	32	9	6.928203	32	5.4%	18.00 [14.92, 21.08]		
Vu 2014	11.1	5.311309	30	6.6	4.948737	30	5.6%	4.50 [1.90, 7.10]		
e 2011	12	8.544004	30	8	9.539392	30	4.7%	4.00 [-0.58, 8.58]		
'uan 2011	5.31	5.286388	89	1.47	5.829691	89	5.9%	3.84 [2.21, 5.47]		
hai 2009.	21	4.358899	30	19.49	3.464102	30	5.8%	1.51 [-0.48, 3.50]		
.ou 2011	18	8.544004	30	9	4.582576	30	5.2%	9.00 [5.53, 12.47]		
Subtotal (95% CI)			392			392	55.4%	7.32 [4.21, 10.43]	•	
leterogeneity: Tau² = est for overall effect:				(P < 0.0)	0001); I² = 9	4%				
fotal (95% CI)			724			683	100.0%	6.80 [4.68, 8.91]	•	
Heterogeneity: Tau ² =	19.13; C	hi ^z = 283.86	. df = 17	(P < 0.)	00001); I ² =	94%				
		(P < 0.0000°							-20 -10 0 10 20	






Figure S2. Subgroup analysis stratified by different years of Shengmai injection for changes in left ventricular ejection fractions (%)





Figure S3. Subgroup analysis stratified by different follow-up of Shengmai injection for changes in left ventricular ejection fractions (%)

	Sher	ngmai inject	ion	Bas	sic treatme	nt		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
3.3.1 ≥ 60 ml									
Chen 2010	24.2	4.746578	50	4.1	4.2	50	9.5%	20.10 [18.34, 21.86]	
Lai 2018	24.75	26.19881	65	8.45	19.46776	65	7.1%	16.30 [8.37, 24.23]	
Pan 2013	13.49	4.453358	34	8.85	4.227907	34	9.5%	4.64 [2.58, 6.70]	
Shi 2001	19	7	82	4	8.185353	41	9.2%	15.00 [12.07, 17.93]	
Sun 2013	23.2	5.95567	30	16.9	4.869292	30	9.3%	6.30 [3.55, 9.05]	
Xu 2004	8	7.830709	50	4	6.548282	26	9.1%	4.00 [0.68, 7.32]	
Subtotal (95% CI)			311			246	53.7%	10.92 [4.36, 17.48]	
Heterogeneity: Tau ² =	= 63.37; C	hi ^z = 174.29	, df = 5 i	(P < 0.0	0001); I ^z = 9	7%			
Test for overall effect:	Z = 3.26	(P = 0.001)							
3.3.2 < 60 ml									
Ding 2012	11.96	7.409474	40	8.02	7.418275	40	9.1%	3.94 [0.69, 7.19]	
Wen 2013	24.1	4.413615	32	10.7	4.613025	32	9.4%	13.40 [11.19, 15.61]	
Ye 2011	11	7.211103	30	8	7	30	9.0%	3.00 [-0.60, 6.60]	
Zhai 2009	31.3	5.288667	30	14.3	4.107311	30	9.4%	17.00 [14.60, 19.40]	
Zou 2011	20.43	5.729747	30	15.3	4.531004	30	9.3%	5.13 [2.52, 7.74]	
Subtotal (95% CI)			162			162	46.3%	8.58 [3.03, 14.14]	
Heterogeneity: Tau ² =	= 38.03; C	hi ² = 83.07,	df = 4 (F	o < 0.00	001); P= 95	96			
Test for overall effect:	Z = 3.03	(P = 0.002)							
Total (95% CI)			473			408	100.0%	9.81 [5.67, 13.96]	-
Heterogeneity: Tau ² =	= 46.17; C	hi ² = 261.75	, df = 10) (P < 0.	00001); I ^z =	96%		a a a <u>-</u>	
Test for overall effect:									-20 -10 0 10 20
Test for subaroup dif				P = 0.59	0 I ² = 0%				Favours [Basic treatment] Favours [Shengmai injection]







Figure S5. Subgroup analysis stratified by different years of Shengmai injection for changes in Stroke volume (ml)

	Sher	ngmai injecti	ion	Bas	sic treatme	nt		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
2.3.1 ≥ 3 weeks									
Chen 2010	24.2	4.746578	50	4.1	4.2	50	9.5%	20.10 [18.34, 21.86]	
Ding 2012	11.96	7.409474	40	8.02	7.418275	40	9.1%	3.94 [0.69, 7.19]	
Lai 2018	24.75	26.19881	65	8.45	19.46776	65	7.1%	16.30 [8.37, 24.23]	
Pan 2013	13.49	4.453358	34	8.85	4.227907	34	9.5%	4.64 [2.58, 6.70]	
Shi 2001	19	7	82	4	8.185353	41	9.2%	15.00 [12.07, 17.93]	
Sun 2013	23.2	5.95567	30	16.9	4.869292	30	9.3%	6.30 [3.55, 9.05]	
Wen 2013	24.1	4.413615	32	10.7	4.613025	32	9.4%	13.40 [11.19, 15.61]	the second se
Ye 2011	11	7.211103	30	8	7	30	9.0%	3.00 [-0.60, 6.60]	
Zhai 2009	31.3	5.288667	30	14.3	4.107311	30	9.4%	17.00 [14.60, 19.40]	
Zou 2011	20.43	5.729747	30	15.3	4.531004	30	9.3%	5.13 [2.52, 7.74]	
Subtotal (95% CI)			423			382	90.9%	10.40 [6.05, 14.74]	
Heterogeneity: Tau ² =	= 46.09; C	hi ² = 243.24	, df = 9	(P < 0.0	0001); I ^z = 9	6%			
Test for overall effect	Z = 4.69	(P < 0.0000	1)						
2.3.2 < 3 weeks									
(u 2004	8	7.830709	50	4	6.548282	26	9.1%	4.00 [0.68, 7.32]	
Subtotal (95% CI)			50			26	9.1%	4.00 [0.68, 7.32]	•
Heterogeneity: Not ap	oplicable								
Test for overall effect	Z = 2.36	(P = 0.02)							
Total (95% CI)			473			408	100.0%	9.81 [5.67, 13.96]	-
Heterogeneity: Tau ² =	= 46.17; C	hi ^z = 261.75	. df = 10) (P < 0.	00001); I ^z =	96%			
Test for overall effect:				21					-20 -10 0 10 20
To at fair and an arrival									Favours (Basic treatment) Favours (Shengmai injection)

Test for subaroup differences: Chi² = 5.26. df = 1 (P = 0.02). l² = 81.0%

Figure S6. Subgroup analysis stratified by different follow-up of Shengmai injection for changes in Stroke volume (ml)

tudy or Subgroup .4.1 ≥ 60 ml	Mean				sic treatmen			Mean Difference	Mean Difference
		SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
h									
hen 2010	2.47	0.443058	50	1.71	0.4531	50	9.7%	0.76 [0.58, 0.94]	
ai 2018	2.34	1.993815	65	0.93	2.023191	65	6.5%	1.41 [0.72, 2.10]	
an 2013	1.66	1.091375	34	0.64	1.008167	34	7.8%	1.02 [0.52, 1.52]	
hi 2001	1.63	1.167733	82	0.64	1.196161	41	8.2%	0.99 [0.55, 1.43]	
un 2013	1.6	0.52915	30	0.4	0.43589	30	9.4%	1.20 [0.95, 1.45]	
u 2004	0.67	0.393954	50	0.39	0.615061	26	9.3%	0.28 [0.02, 0.54]	
ubtotal (95% CI)			311			246	50.8%	0.90 [0.58, 1.22]	-
leterogeneity: Tau ² =	0.12; Ch	i ² = 30.14, d	f= 5 (P	< 0.000	1); I ^z = 83%				
est for overall effect:	Z= 5.48	(P < 0.0000	1)						
.4.2 < 60 ml									
ing 2012	1.27	0.72581	40	0.83	0.514684	40	9.2%	0.44 [0.16, 0.72]	
ong 2004	3	0.180278	30	1.3	0.353412	20	9.7%	1.70 [1.53, 1.87]	
/en 2013	2.76	0.381576	32	1.5	0.458258	32	9.5%	1.26 [1.05, 1.47]	
e 2011	1.4	1.311488	30	0.7	1.352775	30	6.6%	0.70 [0.03, 1.37]	
hai 2009	1.3	1.216553	30	0.5	1,479865	30	6.5%	0.80 [0.11, 1.49]	· · · · · · · · · · · · · · · · · · ·
ou 2011	1.5	0.953939	30	0.61	1.126943	30	7.6%	0.89 [0.36, 1.42]	
ubtotal (95% CI)			192			182	49.2%	0.99 [0.52, 1.46]	
leterogeneity: Tau ² =	0.29; Ch	i ² = 66.57, d	f= 5 (P	< 0.000	01); I ^z = 92%				
est for overall effect:	Z= 4.15	(P < 0.0001))						
otal (95% Cl)			503			428	100.0%	0.96 [0.66, 1.25]	•
leterogeneity: Tau ² =	0.23 Ch	$i^2 = 128.94$	df = 11	P < 0.0	0001): 12 = 9	1%			
est for overall effect:				. 0.0				-2	-1 0 1 2 Favours [Basic treatment] Favours [Shengmai injection]



	Sher	igmai injecti	ion	Bas	sic treatme	nt		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight IV, Random, 95% (IV, Random, 95% Cl
4.4.1 ≥ 65 years									
Ding 2012	1.27	0.72581	40	0.83	0.514684	40	9.2%	0.44 [0.16, 0.72]	
Shi 2001	1.63	1.167733	82	0.64	1.196161	41	8.2%	0.99 [0.55, 1.43]	
Zou 2011	1.5	0.953939	30	0.61	1.126943	30	7.6%	0.89 [0.36, 1.42]	
Subtotal (95% CI)			152			111	25.0%	0.73 [0.35, 1.11]	
Heterogeneity: Tau ² =	0.07; Ch	i ² = 5.26, df	= 2 (P =	0.07); P	² = 62%				
Test for overall effect:	Z= 3.75	(P = 0.0002))	1998					
4.4.2 < 65 years									
Chen 2010	2 47	0.443058	50	1.71	0.4531	50	9.7%	0.76 [0.58, 0.94]	
Kong 2004	3	0.180278	30	1.3	0.353412	20	9.7%	1.70 [1.53, 1.87]	
Lai 2018	2.34	1.993815	65	0.93	2.023191	65	6.5%	1.41 [0.72, 2.10]	
Pan 2013		1.091375	34	0.64	1.008167	34	7.8%	1.02 [0.52, 1.52]	
Sun 2013	1.6	0.52915	30	0.4	0.43589	30	9.4%	1.20 [0.95, 1.45]	
Wen 2013	2.76	0.381576	32	1.5	0.458258	32	9.5%	1.26 [1.05, 1.47]	
Xu 2004	0.67	0.393954	50	0.39	0.615061	26	9.3%	0.28 [0.02, 0.54]	
Ye 2011	1.4	1.311488	30	0.7	1.352775	30	6.6%	0.70 [0.03, 1.37]	
Zhai 2009	1.3	1.216553	30	0.5	1.479865	30	6.5%	0.80 (0.11, 1.49)	
Subtotal (95% CI)			351			317	75.0%	1.02 [0.67, 1.37]	
Heterogeneity: Tau ² =	0.24: Ch	i ² = 107.34.	df = 8 (F	< 0.00	001); I ² = 93	1%			
Test for overall effect:					869				
Total (95% CI)			503			428	100.0%	0.96 [0.66, 1.25]	•
Heterogeneity: Tau ² =	0.23; Ch	i ² = 128.94,	df = 11	(P < 0.0	0001); I ^z = 9	11%			
Test for overall effect:	Z= 6.27	(P < 0.0000	1)	63	0.02				
Test for subaroup diff	(erences:	Chi ² = 1.21.	df = 1 (P = 0.27), $ ^2 = 17.4\%$	6			Favours [Basic treatment] Favours [Shengmai injection]

Figure S8. Subgroup analysis stratified by different years of Shengmai injection for changes in Cardiac output (l/min)




Figure S9. Subgroup analysis stratified by different follow-up of Shengmai injection for changes in Cardiac output (l/min)

	Sher	ngmai inject	ion	Bas	sic treatme	nt		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
3.5.1 ≥ 60 ml									
Chen 2010	2.13	0.217025	50	1.8	0.190788	50	11.2%	0.33 [0.25, 0.41]	-
Lai 2018	1.58	1.24503	65	0.42	1.278554	65	6.6%	1.16 [0.73, 1.59]	
Pan 2013	0.91	0.713583	34	0.5	0.701498	34	8.0%	0.41 [0.07, 0.75]	
Shi 2001	0.63	0.465081	82	0.45	0.298161	41	10.7%	0.18 [0.04, 0.32]	
Sun 2013	1.1	0.43589	30	0.5	0.34641	30	10.0%	0.60 [0.40, 0.80]	
Xu 2004	0.14	0.660908	50	0.01	0.596574	26	8.6%	0.13 [-0.16, 0.42]	
Subtotal (95% CI)			311			246	55.1%	0.42 [0.23, 0.60]	•
Heterogeneity: Tau ² =	0.04; Ch	ni² = 27.77, d	lf= 5 (P	< 0.000	1); I ² = 82%				
Fest for overall effect	Z = 4.37	(P < 0.0001))						
3.5.2 < 60 ml									
Kong 2004	2.4	1.113553	30	1.6	1.1	20	4.5%	0.80 [0.17, 1.43]	
Ven 2013	2.38	0.220681	32	1.75	0.26	32	10.9%	0.63 [0.51, 0.75]	
re 2011	0.5	0.608276	30	0.3	0.34641	30	9.2%	0.20 [-0.05, 0.45]	
Zhai 2009	1.35	0.43589	30	0.44	0.31241	30	10.1%	0.91 [0.72, 1.10]	
Zou 2011	1.3	0.458258	30	0.5	0.2	30	10.2%	0.80 [0.62, 0.98]	
Subtotal (95% CI)			152			142	44.9%	0.66 [0.44, 0.88]	•
-leterogeneity: Tau ² =	0.05; Ch	ni ² = 22.16, d	If = 4 (P :	= 0.000	2); I ² = 82%				
Test for overall effect	Z = 5.84	(P < 0.0000	1)						
Fotal (95% CI)			463			388	100.0%	0.53 [0.36, 0.70]	•
Heterogeneity: Tau ² =	0.07; Ch	ni ² = 91.49, d	lf = 10 (F	< 0.00	001); l ² = 89	%		· · · · · · · · · · · · · · · · · · ·	
Test for overall effect:					882)			-2	-1 U 1
Test for subaroup dif				P = 0.10	0 P = 63.7%				Favours [Basic treatment] Favours [Shengmai injection]

Figure S10. Subgroup analysis stratified different doses of Shengmai injection for changes in Cardiac index (l/min)

	Sher	ngmai injecti	on	Bas	sic treatmen	nt		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean SD		Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
4.5.1 ≥ 65 years									
Shi 2001	0.63	0.465081	82	0.45	0.298161	41	10.7%	0.18 [0.04, 0.32]	
Zou 2011	1.3	0.458258	30	0.5	0.2	30	10.2%	0.80 [0.62, 0.98]	
Subtotal (95% CI)			112			71	21.0%	0.49 [-0.12, 1.09]	
Heterogeneity: Tau ² =	= 0.19; Ch	ni ² = 29.26, dt	f=1 (P	< 0.000	01); I ² = 97%				
Test for overall effect:	Z=1.57	(P = 0.12)							
4.5.2 < 65 years									
Chen 2010	2.13	0.217025	50	1.8	0.190788	50	11.2%	0.33 [0.25, 0.41]	+
Kong 2004	2.4	1.113553	30	1.6	1.1	20	4.5%	0.80 [0.17, 1.43]	20
Lai 2018	1.58	1.24503	65	0.42	1.278554	65	6.6%	1.16 [0.73, 1.59]	
Pan 2013	0.91	0.713583	34	0.5	0.701498	34	8.0%	0.41 [0.07, 0.75]	
Sun 2013	1.1	0.43589	30	0.5	0.34641	30	10.0%	0.60 [0.40, 0.80]	
Wen 2013	2.38	0.220681	32	1.75	0.26	32	10.9%	0.63 [0.51, 0.75]	
Xu 2004	0.14	0.660908	50	0.01	0.596574	26	8.6%	0.13 [-0.16, 0.42]	10 10 10 10 10 10 10 10 10 10 10 10 10 1
Ye 2011	0.5	0.608276	30	0.3	0.34641	30	9.2%	0.20 [-0.05, 0.45]	
Zhai 2009	1.35	0.43589	30	0.44	0.31241	30	10.1%	0.91 [0.72, 1.10]	
Subtotal (95% CI)			351			317	79.0%	0.55 [0.36, 0.73]	•
Heterogeneity: Tau ² =	= 0.06; Ch	ni ² = 61.13, dt	f=8(P	< 0.000	01); I ² = 87%				
Test for overall effect:	Z = 5.75	(P < 0.00001	1)						
Total (95% CI)			463			388	100.0%	0.53 [0.36, 0.70]	◆
Heterogeneity: Tau ² =	= 0.07; Ch	ni ² = 91.49, dt	f = 10 (F	< 0.00	001); l ^z = 89'	%		+	
Test for overall effect:	Z= 6.13	(P < 0.00001	I)					-2	The second second and the second seco
Test for subaroup dif	ferences:	Chi ² = 0.03.	df = 1 (P = 0.86	i), $ ^2 = 0\%$				Favours (Basic treatment) Favours (Shengmai injection)


Figure S11. Subgroup analysis stratified by different years of Shengmai injection for changes in Cardiac index (l/min)

	Sher	igmai injecti	ion	Bas	sic treatme	nt		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% Cl
2.5.1 ≥ 3 weeks									
Chen 2010	2.13	0.217025	50	1.8	0.190788	50	11.2%	0.33 [0.25, 0.41]	-
Kong 2004	2.4	1.113553	30	1.6	1.1	20	4.5%	0.80 [0.17, 1.43]	
Lai 2018	1.58	1.24503	65	0.42	1.278554	65	6.6%	1.16 [0.73, 1.59]	
Pan 2013	0.91	0.713583	34	0.5	0.701498	34	8.0%	0.41 [0.07, 0.75]	
Shi 2001	0.63	0.465081	82	0.45	0.298161	41	10.7%	0.18 [0.04, 0.32]	-+
Sun 2013	1.1	0.43589	30	0.5	0.34641	30	10.0%	0.60 [0.40, 0.80]	
Wen 2013	2.38	0.220681	32	1.75	0.26	32	10.9%	0.63 [0.51, 0.75]	
Ye 2011	0.5	0.608276	30	0.3	0.34641	30	9.2%	0.20 [-0.05, 0.45]	
Zhai 2009	1.35	0.43589	30	0.44	0.31241	30	10.1%	0.91 [0.72, 1.10]	
Zou 2011	1.3	0.458258	30	0.5	0.2	30	10.2%	0.80 [0.62, 0.98]	
Subtotal (95% CI)			413			362	91.4%	0.57 [0.39, 0.75]	•
Heterogeneity: Tau ² =	0.07: Ch	i ² = 86.54. d	f=9(P	< 0.000	01): I ^z = 909	6			
Test for overall effect:	Z = 6.29	(P < 0.00001	1)		30				
2.5.2 < 3 weeks									
Xu 2004	0.14	0.660908	50	0.01	0.596574	26	8.6%	0.13 [-0.16, 0.42]	
Subtotal (95% CI)			50			26	8.6%	0.13 [-0.16, 0.42]	
Heterogeneity: Not ap	plicable							0 5 5	
Test for overall effect:		(P = 0.39)							
Total (95% CI)			463			388	100.0%	0.53 [0.36, 0.70]	•
Heterogeneity: Tau ² =	0.07: Ch	i [≇] = 91.49. d	f = 10 (F	< 0.00	001): I ^z = 89				t t t
Test for overall effect:				,	900				-2 -1 0 1
Test for subaroup diff				P = 0.01) $ ^2 = 84.2\%$	6			Favours [Basic treatment] Favours [Shengmai injection]

Figure S12. Subgroup analysis stratified by different follow-up of Shengmai injection for changes in Cardiac index (l/min)

Supplementary Materials 2: Results of sensitivity analysis Table S1. Sensitivity analysis excluding trials with a high risk of bias

0	A 1	No. o	f pts	Mean difference	II
Outcome	Analysis	Shengmai	Control	- (95% CI)	Heterogeneity
left ventricular ejection	Main analysis	724	683	6.80 (4.68, 8.91)	I ² =99%, P<0.0001
fractions					
	Excluding trials with	624	583	6.85 (4.36, 9.34)	I ² =95%, P<0.0001
	high risk of bias				
Response to treatment	Main analysis	662	595	2.89 (2.10, 3.99)	I ² =0%, P<0.0001
	Excluding trials with	562	495	2.77 (1.95, 3.92)	I ² =0%, P<0.0001
	high risk of bias				
Stroke volume	Main analysis	473	408	9.81 (5.67, 13.96)	I ² =96%, P<0.00001
	Excluding trials with	443	378	10.18(5.71,14.64)	I ² =96%, P<0.00001
	high risk of bias				
Cardiac output	Main analysis	503	428	0.96 (0.66, 1.25)	I ² =91%, P<0.00001
	Excluding trials with	473	398	0.93 (0.60, 1.26)	I ² =92%, P<0.00001
	high risk of bias				
Cardiac index	Main analysis	463	388	0.53 (0.36, 0.70)	I ² =89%, P<0.00001
	Excluding trials with	433	358	0.53 (0.34, 0.71)	I ² =90%, P<0.00001
	high risk of bias				
six-minute walk	Main analysis	125	118	70.67	I2=84%, P=0.004
				(22.92,118.42)	
	Excluding trials with	95	88	64.23	I2=92%, P=0.11
	high risk of bias			(-13.55,142.02)	
Brain natriuretic peptide	Main analysis	197	195	-284.66 (-353.73,	I ² =0%, P<0.00001
				-215.59)	
	Excluding trials with	197	195	-284.66 (-353.73,	I ² =0%, P<0.00001
	high risk of bias			-215.59)	








Figure S13. Funnel plot of left ventricular ejection fractions








Figure S16. Funnel plot of cardiac output




Figure S17. Funnel plot of cardiac index